抗SARS-CoV-2疫苗的超敏反应:嗜碱性粒细胞对辅料的反应性
研究对89例疑似抗SARS-CoV-2疫苗超敏反应患者(56%有迟发型皮肤黏膜表现)和156例疫苗接种前受试者进行嗜碱性粒细胞活化试验(BAT),检测聚乙二醇3350、DMG-PEG 2000、PEG 20000、聚山梨酯-80和氨丁三醇。阳性BAT与迟发反应发生(p=0.010)和缓解(p=0.011)相关,两组对DMG-PEG 2000的BAT阳性率均高于其他辅料(p<0.001)。未接种者DMG-PEG 2000反应性(6%)低于已接种者(35%,p<0.001),且与mRNA-1273接种相关。
要点
- 阳性BAT与迟发型超敏反应的发生和缓解相关。
- 两组中BAT对DMG-PEG 2000的阳性率均高于其他辅料。
- 未接种者DMG-PEG 2000反应性低于已接种者,且与mRNA-1273接种相关。
核心结论
- DMG-PEG 2000的BAT可能对迟发型超敏反应患者具有诊断价值。
- 自然免疫可能是嗜碱性粒细胞活化的关键因素。
研究设计与样本
- 研究纳入89例疑似抗SARS-CoV-2疫苗超敏反应患者(56%有迟发型皮肤黏膜表现)和156例疫苗接种前受试者,进行BAT检测聚乙二醇3350、DMG-PEG 2000、PEG 20000、聚山梨酯-80和氨丁三醇。
主要发现
- 阳性BAT与迟发反应发生(p=0.010)和缓解(p=0.011)相关。
- 两组中BAT对DMG-PEG 2000的阳性率均高于其他辅料(p<0.001)。
- 未接种者DMG-PEG 2000反应性(6%)低于已接种者(35%,p<0.001),且与mRNA-1273接种相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basophil activation test (BAT) can tackle multiple mechanisms underlying acute and delayed hypersensitivity to drugs and vaccines and might complement conventional allergy diagnostics but its role in anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-related hypersensitivity is ill-defined. Therefore, 89 patients with possible hypersensitivity (56 % with delayed mucocutaneous manifestations) to anti-SARS-CoV-2 vaccines were tested with BAT for Macrogol 3350, DMG-PEG 2000, PEG 20000, polysorbate-80 and trometamol and compared to 156 subjects undergoing pre-vaccine BAT. A positive BAT was associated with delayed reaction onset (p = 0.010) and resolution (p = 0.011). BAT was more frequently positive to DMG-PEG 2000 than to other excipients in both groups (p < 0.001). DMG-PEG 2000 reactivity was less frequent in vaccine-naïve (6 %) than vaccinated subjects (35 %, p < 0.001) and associated with mRNA-1273 vaccination. DMG-PEG 2000 BAT might therefore have a diagnostic role in subjects with delayed hypersensitivity reactions. Natural immunity might be a key player in basophil activation.
引用
- Pignatti P, Ramirez GA, Russo M, et al. Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients. Vaccine. 2023. PMID: 37349223. doi:10.1016/j.vaccine.2023.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。